Business Segments · Research and development:
Reportable Segment — Research and development:
Biogen Reportable Segment — Research and development: decreased by 3.5% to $172.80M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 3.2%, from $178.50M to $172.80M. Over 3 years (FY 2022 to FY 2025), Reportable Segment — Research and development: shows relatively stable performance with a -1.7% CAGR.
Analysis
StatementSegment
CategoryCapital Allocation
SignalContext dependent
VolatilityModerate
First reportedQ1 2022
Last reportedQ1 2026
Rolls up toR&D
How to read this metric
An increase signals a focus on pipeline expansion, while a decrease may suggest cost-cutting or a shift in strategic R&D priorities.
Detailed definition
This metric tracks the capital and operational expenditures dedicated to discovering and developing new pharmaceutical c...
Peer comparison
Commonly reported as 'R&D Expense' by all biopharmaceutical peers.
Metric ID:
biib_segment_reportable_segment_research_and_developmentHistorical Data
17 periods
| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $182.40M | $182.40M | $182.40M | $182.40M | $213.83M | $213.83M | $213.83M | $213.83M | $163.00M | $176.40M | $221.50M | $186.90M | $178.50M | $168.20M | $167.10M | $179.10M | $172.80M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | +17.2% | +0.0% | +0.0% | +0.0% | -23.8% | +8.2% | +25.6% | -15.6% | -4.5% | -5.8% | -0.7% | +7.2% | -3.5% |
| YoY Change | — | — | — | — | +17.2% | +17.2% | +17.2% | +17.2% | -23.8% | -17.5% | +3.6% | -12.6% | +9.5% | -4.6% | -24.6% | -4.2% | -3.2% |
Range$163.00M – $221.50M
CAGR-1.3%
Avg YoY Growth-0.6%
Median YoY Growth-3.2%
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Biogen's reportable segment — research and development:?
- Biogen (BIIB) reported reportable segment — research and development: of $172.80M in Q1 2026.
- How has Biogen's reportable segment — research and development: changed year-over-year?
- Biogen's reportable segment — research and development: decreased by 3.2% year-over-year, from $178.50M to $172.80M.
- What is the long-term trend for Biogen's reportable segment — research and development:?
- Over 3 years (2022 to 2025), Biogen's reportable segment — research and development: has grown at a -1.7% compound annual growth rate (CAGR), from $729.60M to $692.90M.
- What does reportable segment — research and development: mean?
- The total costs incurred for research and clinical development activities within the business segment.